关于 ASCO 会议

美国临床肿瘤学会（ASCO）创建于 1964 年，是全球规模最大、学术水平最高的临床肿瘤学专业组织。其年会被誉为肿瘤学界的 “奥斯卡”，每年吸引全球 160 多个国家、超 4 万名专业人士参会，集中发布癌症临床前沿数据、突破性治疗方案及创新药物研发成果。

2026 年 ASCO 年会中，中国多项研究成功入选口头报告及最新突破性摘要（LBA），充分彰显中国创新药研发正从 “跟随研发” 稳步迈向 “源头创新” 的全新开展阶段。

近期，K8凯发医药团队赴美国芝加哥参加 2026 年美国临床肿瘤学会（ASCO）全球年会。作为全球肿瘤领域最具影响力的顶级学术盛会，ASCO 年会汇聚了世界各地顶尖科研组织、生物医药企业、临床专家及产业投资组织，共探肿瘤诊疗前沿趋势与创新开展方向。

会议期间，K8凯发医药与来自美国、欧洲及亚洲的多家创新生物医药企业召开面对面深度研讨，重点围绕脑肿瘤治疗领域行业开展趋势、临床未满足需求以及国际产学研潜在合作机遇，展开充分研讨与精准对接。　

研讨环节中，公司重点介绍了全球首创小分子脂质体肿瘤微环境治疗药物——JRF101的最新研发进展。JRF101在二次及以上复发/进展胶质母细胞瘤患者中显示出持续的生存获益趋势。II期试验组3、6、9个月生存率分别达到85.0%、53.8%和39.3%，均高于同期对照组。完成规范疗程患者的敏感性分析显示，9个月生存率进一步提升至52.7%。在二次及以上复发患者中，JRF101仍维持较高生存率水平。同时，JRF101表现出良好的安全性特征，≥3级不良反应发生率仅26.3%，显著低于对照组的50%，且未发生严重骨髓抑制，体现出较好的风险收益比。JRF101在复发性胶质母细胞瘤患者中展现出良好的治疗潜力，患者的中位总生存期（mOS）相比于历史参考数据有了显著提升。但由于样本量较小，相关结果仍需在后续扩大样本的临床研究中进一步验证。

复发性胶质母细胞瘤是当前全球肿瘤治疗领域的重大临床难题，现有治疗手段有限，患者整体预后较差，临床上仍存在巨大未满足医疗需求。K8凯发医药所取得的阶段性临床进展，受到多家国际参会企业高度关注，为公司后续召开跨境技术合作、海外临床开发及国际化布局奠定了良好基础。

下一步，公司计划在国内顺利完成 Ⅱ 期临床研究并形成正式数据报告后，持续探索进入美国临床开发的机会（JRF101已取得FDA临床许可、孤儿药认定）。同时，K8凯发医药也希望寻求具有共同愿景的国际合作伙伴，顺利获得资源共享与优势互补，共同推进创新疗法开发，为全球复发性GBM患者带来更多治疗选择。

未来，K8凯发医药将持续坚守创新驱动研发战略，深度融入全球创新药研发体系，依托自有脂质体技术平台与天然产物抗肿瘤研发优势，持续有助于高临床价值的创新成果走向国际市场，助力中国原创生物医药成果惠及全球患者。

Jinrui Highlights JRF101 Development Progress at the 2026 ASCO Annual Meeting

About ASCO

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s largest and most authoritative academic organization in clinical oncology. Its annual meeting is known as the "Oscars of Oncology", attracting over 40,000 professionals from more than 160 countries across the globe. It serves as a core platform for releasing cutting-edge clinical trial data, breakthrough treatment regimens and innovative drug R&D achievements in oncology.

At the 2026 ASCO Annual Meeting, multiple Chinese studies were selected for oral presentations and Late-Breaking Abstracts (LBA), fully demonstrating that China’s innovative drug R&D is steadily advancing from follow-on research to original innovation.

Jinrui recently attended the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, where members of the company's team met with biotechnology and pharmaceutical industry representatives from North America, Europe, and Asia.

The discussions focused on emerging developments in neuro-oncology, ongoing challenges in the treatment of glioblastoma, and potential opportunities for scientific and business collaboration. During these exchanges, Jinrui introduced its development programs and shared updates on JRF101, the company's investigational therapy for recurrent glioblastoma (GBM).

JRF101 has demonstrated encouraging clinical activity in patients with recurrent or progressive GBM. In the study, 3-, 6-, and 9-month survival rates reached 85.0%, 53.8%, and 39.3%, respectively, exceeding those observed in the control group. Among patients who completed the planned treatment course, the 9-month survival rate increased to 52.7%. The therapy also demonstrated a favorable safety profile, with a lower incidence of Grade 3 or higher adverse events than the control arm and no severe myelosuppression observed.

Recurrent glioblastoma remains one of the most difficult-to-treat cancers, with limited therapeutic options and poor clinical outcomes. Jinrui believes that continued scientific innovation and international collaboration will be important to advancing new treatment approaches for patients with this disease.

The company is currently focused on completing its ongoing Phase II clinical study in China and generating a comprehensive clinical data package. Jinrui is also exploring opportunities to support the future global development of JRF101. The program has received FDA clearance for clinical investigation in the United States and has been granted Orphan Drug Designation.

By engaging with stakeholders across the global biotechnology ecosystem, Jinrui aims to build relationships that can support the continued development of innovative therapies for patients with high unmet medical needs.